EdwardBrianGaronMD

Oncology • Santa Monica, CA

Assistant Professor, Medicine, UCLA School of Medicine

Join to view full profile

Dr. Garon is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Garon's full profile

Already have an account?

Office
2020 Santa Monica Blvd., 6th Floor
Santa Monica, CA 90404
Phone+1 310-829-5471

Fax+1 310-829-5471

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2003 - 2006
University of ChicagoResidency, Internal Medicine, 1999 - 2002
Washington University in St. Louis School of MedicineClass of 1999

Certifications & Licensure

CA State Medical License 2003 - 2026
IL State Medical License 1999 - 2005
American Board of Internal Medicine Medical Oncology

Clinical Trials

Erlotinib With or Without Fulvestrant in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2004 Oct 28
Completed
Phase 2
Celecoxib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2009 Jan 01
Completed
Phase 1
Genistein in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery Start of enrollment: 2009 May 01
Withdrawn
Phase 2
Dichloroacetate (DCA) in Patients With Previously Treated Metastatic Breast or Non-Small Cell Lung Cancer (NSCL) Start of enrollment: 2009 Dec 01
Terminated
Phase 2
Exemestane, Pemetrexed Disodium, and Carboplatin in Treating Post-Menopausal Women With Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2012 Sep 07
Completed
Phase 1
Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2014 Jan 31
Completed
Phase 1
Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer Start of enrollment: 2016 Sep 15
Completed
Phase 2
Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC Start of enrollment: 2017 Sep 20
Completed
Phase 1
CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer Start of enrollment: 2019 Jul 08
Active, not recruiting
Phase 1
Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer Start of enrollment: 2024 Mar 20
Recruiting
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

3 citations
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON ...
Solange Peters, Byoung Chul Cho, Alexander V Luft, Jorge Alatorre-Alexander, Sarayut Lucien Geater
Journal of Thoracic Oncology. 2025-01-01
FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004).
Alexander Spira, Byoung Chul Cho, Enriqueta Felip, Edward B Garon, Koichi Goto
Lung Cancer. 2024-12-28
RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC.
Kazuhiko Nakagawa, Edward B Garon, Takashi Seto, Makoto Nishio, Santiago Ponce Aix
Journal of Thoracic Oncology. 2024-11-30

Journal Articles

Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer
Edward B Garon, Maeve Waldron-Lynch, The New England Journal of Medicine

Lectures

Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001.
2019 ASCO Annual Meeting - 6/1/2019
Safety and activity of durvalumab + tremelimumab in immunotherapy (IMT)-pretreated advanced NSCLC patients.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Responses and durability in NSCLC treated with pegilodecakin and anti-PD-1.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Authored Content

Controversies, Difficult Questions Arise in NSCLC Amid New DataFebruary 2024

Press Mentions

Dr. Garon on Considerations Regarding the Use of Perioperative Immunotherapy in Lung CancerJuly 4th, 2024
High-Dose Radiotherapy with Chemotherapy Effective in Treating People with Non-Small Cell Lung CancerJanuary 11th, 2024
How a Biomarker Test Saved This Lung Cancer Survivor’s LifeNovember 30th, 2022
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member